Myeloma

Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology.

The data demonstrated that the addition of Ninlaro to Revlimid and dexamethasone led to a 13.5-month increase in median progression-free survival, compared with placebo. However, the data failed to meet the threshold for statistical significance.

Forty percent of patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) or greater of CLR 131.

When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.

There have been several drug approvals and updates from the Food and Drug Administration (FDA) in the cancer space over the last several weeks.

The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.

In addition to improving progression-free survival, researchers have found single-agent Ninlaro (ixazomib) to be a tolerable option in patients with newly diagnosed multiple myeloma who have also already undergone an autologous stem cell transplant.

The Food and Drug Administration (FDA) has approved the expansion of Kyprolis (carfilzomib) in combination to with Darzalex (daratumumab) plus dexamethasone in once- and twice-weekly dosing regimens for the treatment of patients with relapsed or refractory multiple myeloma who have received a maximum of three prior lines of therapy.

Despite recent advances in the treatment of multiple myeloma, more must be done to find effective treatment options for patients with advanced disease, according to Dr. Luciano J. Costa.

While the use of CAR-T cell therapy is currently still being investigated in patients with multiple myeloma, Dr. Nina Shah of the UCSF Helen Diller Family Comprehensive Cancer Center believes that these clinical trials will be what ultimately moves the field forward.

The future of multiple myeloma is heading toward combination therapies and CAR-T cell treatments, according to Dr. Betsy O'Donnell.

On social media, CURE® recently asked its readers to share how they pamper and treat themselves during or after their cancer treatment. Here, we share some of their responses.

The Food and Drug Administration approved Blenrep to treat patients with relapsed/refractory multiple myeloma.

On social media, CURE® recently asked its readers to share the advice they would give someone looking to help a friend or loved one with cancer. Here, we share some of their responses.

Dr. Parameswaran Hari discusses the importance of understanding a patient’s MRD if they are receiving the maintenance therapy Sarclisa for multiple myeloma.

The use of a mobility aide program in a cancer unit among the Mount Sinai Health System helped 76% of patients hospitalized for their cancer either maintain or improve their mobility scores, helping to reduce excess days spent in the hospital and readmission rates.

Patients with multiple myeloma who were obese or overweight had a trend toward slightly improved progression-free survival and overall survival outcomes compared to patients who had a normal weight, according to data from an exploratory analysis.

A roundup of the latest news and updates for patients with multiple myeloma from CURE®.

The manufacturer is working with the Food and Drug Administration to address any requests including changes to the protocol of the MELANI-01 trial to enhance patient safety.

The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted in favor of the agency approving belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma who have previously received at least four therapies.